

Raf1 Cas9-CKO Strategy


Designer: Design Date:

0,

Huan Fan 2019-7-25

Project Overview






Conditional Knockout strategy



400-9660890

This model will use CRISPR/Cas9 technology to edit the *Raf1* gene. The schematic diagram is as follows:



江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.



The *Raf1* gene has 11 transcripts. According to the structure of *Raf1* gene, exon2 of *Raf1-201* (ENSMUST0000000451.13) transcript is recommended as the knockout region. The region contains start codon ATG.
Knock out the region will result in disruption of protein function.

In this project we use CRISPR/Cas9 technology to modify *Raf1* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.



- According to the existing MGI data, Homozygotes for targeted null mutations are growth retarded, with hypocellular fetal livers, placental anomalies, and defects of skin and lungs, resulting in lethality around mid-gestation. Mice heterozygous for a knock-in allele exhibit hypertrophic cardiomyopathy.
- ≻Transcript *Raf1-206,209* may not be affected.
- The *Raf1* gene is located on the Chr6. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

400-9660890

Gene information (NCBI)



\$?

Raf1 v-raf-leukemia viral oncogene 1 [Mus musculus (house mouse)]

Gene ID: 110157, updated on 31-Jan-2019

Summary

| Official Symbol | Raf1 provided by MGI |
|----------------------|--|
| Official Full Name | v-raf-leukemia viral oncogene 1 provided by MGI |
| Primary source | MGI:MGI:97847 |
| See related | Ensembl:ENSMUSG0000000441 |
| Gene type | protein coding |
| RefSeq status | VALIDATED |
| Organism | Mus musculus |
| Lineage | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; |
| | Muroidea; Muridae; Murinae; Mus; Mus |
| Also known as | 6430402F14Rik, AA990557, BB129353, Craf1, D830050J10Rik, Raf-1, c-Raf, cRaf, v-Raf |
| Expression | Ubiquitous expression in CNS E14 (RPKM 50.6), whole brain E14.5 (RPKM 48.5) and 28 other tissues See more |
| Orthologs | human all |

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

400-9660890

Transcript information (Ensembl)



The gene has 11 transcripts, all transcripts are shown below:

| Transcript ID | bp | Protein | Biotype | CCDS | UniProt | Flags |
|----------------------|---|---|--|--|---|--|
| ENSMUST0000000451.13 | 3070 | <u>648aa</u> | Protein coding | CCDS20441 | Q99N57 | TSL:1 GENCODE basic APPRIS P1 |
| ENSMUST00000112949.7 | 2946 | <u>648aa</u> | Protein coding | CCDS20441 | Q99N57 | TSL:1 GENCODE basic APPRIS P1 |
| ENSMUST00000147979.2 | 613 | <u>205aa</u> | Protein coding | 84 | F6TUC4 | 5' and 3' truncations in transcript evidence prevent annotation of the start and the end of the CDS. CDS 5' and 3' incomplete TSL: |
| ENSMUST00000203759.1 | 538 | <u>96aa</u> | Protein coding | <u>12</u> | A0A0N4SWH5 | CDS 5' incomplete TSL:5 |
| ENSMUST00000203142.1 | 676 | <u>118aa</u> | Nonsense mediated decay | 1.7 | A0A0N4SV36 | CDS 5' incomplete TSL:3 |
| ENSMUST00000130528.7 | 3968 | No protein | Retained intron | | - | TSL:1 |
| ENSMUST00000127503.1 | 2277 | No protein | Retained intron | 84 | - | TSL:1 |
| ENSMUST00000203276.1 | 838 | No protein | Retained intron | 62 | - | TSL:1 |
| ENSMUST00000203826.2 | 745 | No protein | Retained intron | 1.5 | | TSL:5 |
| ENSMUST00000124553.3 | 732 | No protein | Retained intron | | | TSL:5 |
| ENSMUST00000204512.1 | 674 | No protein | Retained intron | 32 | 2 | TSL:3 |
| | ENSMUST000000451.13 ENSMUST00000112949.7 ENSMUST00000147979.2 ENSMUST00000203759.1 ENSMUST00000203142.1 ENSMUST00000130528.7 ENSMUST00000127503.1 ENSMUST00000203826.2 | ENSMUST000000451.13 3070 ENSMUST0000112949.7 2946 ENSMUST0000147979.2 613 ENSMUST0000203759.1 538 ENSMUST0000203142.1 676 ENSMUST0000130528.7 3968 ENSMUST0000127503.1 2277 ENSMUST0000203276.1 638 ENSMUST0000203262.2 745 ENSMUST0000124553.3 732 | ENSMUST00000045110 3070 648aa ENSMUST00001129497 2946 648aa ENSMUST00001479792 613 205aa ENSMUST00002037591 538 96aa ENSMUST00001305267 676 118aa ENSMUST00001275031 2070 No protein ENSMUST00001275031 2127 No protein ENSMUST0000203761 838 No protein ENSMUST00002032626 745 No protein ENSMUST00001245533 742 No protein | ENSMUST0000000451.133070648aaProtein codingENSMUST00000112949.72946648aaProtein codingENSMUST0000147979.2613205aaProtein codingENSMUST0000203759.153896aaProtein codingENSMUST0000203142.1676118aaNonsense mediated decayENSMUST0000130528.73968No proteinRetained intronENSMUST0000127503.12277No proteinRetained intronENSMUST0000203276.1838No proteinRetained intronENSMUST0000203826.2745No proteinRetained intronENSMUST0000124553.3732No proteinRetained intron | ENSMUST0000000451.133070648aaProtein codingCCDS20441ENSMUST0000112949.72946648aaProtein codingCCDS20441ENSMUST0000147979.2613205aaProtein coding-ENSMUST0000203759.153896aaProtein coding-ENSMUST0000203142.1676118aaNonsense mediated decay-ENSMUST0000130528.73968No proteinRetained intron-ENSMUST0000127503.12277No proteinRetained intron-ENSMUST0000203376.1838No proteinRetained intron-ENSMUST0000203276.1745No proteinRetained intron-ENSMUST0000203826.2745No proteinRetained intron-ENSMUST0000124553.3732No proteinRetained intron- | Image: A constraint of the state of the s |

The strategy is based on the design of *Raf1-201* transcript, The transcription is shown below

< Raf1-201 protein coding


Reverse strand -

58.07 kb

Genomic location distribution



400-9660890




江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.


Protein domain





Mouse phenotype description(MGI)





Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data, Homozygotes for targeted null mutations are growth retarded, with hypocellular fetal livers, placental anomalies, and defects of skin and lungs, resulting in lethality around mid-gestation. Mice heterozygous for a knock-in allele exhibit hypertrophic cardiomyopathy.

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

400-9660890



If you have any questions, you are welcome to inquire. Tel: 400-9660890



